Q-omics provides the consensus-scored ITGA6 profile across patient tissues and cancer cell-line models. ITGA6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ITGA6 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ITGA6 RNA expression shows 20,401 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where ITGA6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITGA6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITGA6 survival associations across molecular data types. ITGA6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITGA6 RNA expression–survival associations across cancer types. High ITGA6 expression shows unfavorable associations in UVM, ACC, HNSC, LGG and LUAD, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ITGA6 RNA expression.
This table summarizes ITGA6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ITGA6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITGA6 shows lower tumor expression in BRCA and higher tumor expression in HNSC, LIHC, STAD, LUSC and COAD. The HNSC box plot shows higher ITGA6 RNA expression in tumor versus normal tissue (log2 FC = +2.913, t-test p < 0.001).
This table shows molecular features associated with ITGA6 in patient tissues and cancer cell lines. In patient samples, ITGA6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ITGA6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
